V
Voltron Therapeutics
Precision-guided vaccines enhancing cell-mediated responses for cancer and infectious diseases
About Voltron Therapeutics
Voltron Therapeutics, Inc., founded in 2017, is a biotechnology company focused on developing advanced vaccines for cancer and infectious diseases. Utilizing the proprietary Self Assembling Vaccine Design technology, licensed exclusively from Massachusetts General Hospital and the Vaccine Immunotherapy Center, Voltron aims to improve cell-mediated immune responses. The company targets both oncology and emerging infectious diseases, with initial proof of concept demonstrated in pre-clinical studies for Lassa Fever, Q Fever, ovarian cancer, and HPV-related cancers. Voltron's business model revolves around leveraging cutting-edge research to create effective vaccines, serving healthcare providers and patients in the oncology and infectious disease markets. Revenue is generated through licensing agreements, research grants, and potential future sales of developed vaccines.
Source: Dealroom company dataAt a glance
- Founded
- 2017
- Headquarters
- New York City, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US Department of War
Series A1 investor entered at this stage
Laidlaw & Company
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Voltron Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Voltron Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.